Medivation News

Sr. Vice President and CFO of Medivation Inc. Clarence Patrick Machado sells 20,000 shares of MDVN on 12/07/2009 at an average price of $33.27 a share.

Medivation Inc. boosted the salaries of its four top executives 13.2 percent to 16.4 percent.

Sr. Vice President and CFO of Medivation Inc. Clarence Patrick Machado sells 20,000 shares of MDVN on 11/11/2009 at an average price of $28.28 a share.

"They were extremely hungry for this deal," says Medivation CEO David Hung. Flush with cash, Japanese drug companies are trying to refill their product pipelines through deals with Bay Area companies.

Main Category: Alzheimer's / Dementia Also Included In: Clinical Trials / Drug Trials Article Date: 04 Nov 2009 - 23:00 PST Pfizer Inc and Medivation, Inc.

The last week of October was appropriately marked by treats and tricks. The stock market gyrated from investor ebullience over numbers showing a 3.5 percent growth of the U.S. GDP in the third quarter of 2009, to investor dismay over worries that a drop in consumer spending signals an unsustainable recovery.

Funny cat photos lead to serious Web empire James Temple, Chronicle Staff Writer Ben Huh earned a journalism degree and interned at several newspapers, but he ultimately chose a more practical career path: funny cat photo captions.

San Francisco's Medivation Inc. will receive a cash payment of $110 million from Astellas Pharma Inc.

Medivation Inc. said Tuesday it will receive $110 million and potential milestone payments after signing a development deal with Astellas Pharma Inc.

Medivation Inc. 's investigational prostate cancer drug could win the San Francisco company up to $765 million in a deal with Astellas Pharmaceuticals Inc.

When Medivation Inc. gained clearance in March to start its Phase III trial of MDV3100 in prostate cancer, a company executive told BioWorld Today the firm would consider partnering the drug if the right opportunity came along - as it had for Alzheimer's disease drug Dimebon, which scored a potential $725 million deal with Pfizer Inc.

Astellas Pharma Inc. and Medivation, Inc. announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer.

Main Category: Prostate / Prostate Cancer Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 24 Sep 2009 - 2:00 PDT Medivation, Inc.

For speculative investors aware of the risks associated with a development stage drug company, Karim Rahemtulla looks to Medivation , a play on development of a drug to treat Alzheimer's. In his Xcelerated Profits Report , the advisor explains, "Medivation continues to make good clinical trial progress with its Dimebon drug for Alzheimer's Disease.

Companies mentioned in this article: Medivation, Inc. SAN FRANCISCO, Sept. 9 /PRNewswire-FirstCall/ -- Medivation, Inc.

Pfizer Inc and Medivation, Inc have announced the initiation of a Phase 3 trial of the investigational drug dimebon in patients with Huntington disease.

Pfizer Inc. and Medivation Inc. started a 350-patient, Phase III trial of the drug Dimebon for Huntington Disease.

Pfizer Inc. and Medivation, Inc. Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease NEW YORK & SAN FRANCISCO-- --Pfizer Inc and Medivation, Inc.

An experimental Alzheimer's drug being developed by researchers at Pfizer Inc. in Groton and New London is pointing scientists in surprising new directions as they study the debilitating condition that affects up to 5.3 million Americans.

Researchers and drugmakers studying Alzheimera s disease may need to rethink how the condition cripples the brains of patients based on research in mice released today.